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Summary Sera from C57B1/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich
(allogeneic) and RLI (syngeneic) ascites tumours in BALB/c mice. Sera obtained from mice 24h after Ge-132
administration displayed the greatest antitumour effect and this was dose dependent. Sera prepared from mice
12, 36, or 48h after Ge-132 treatment had no protective effect. Circulating interferon (IFN) was induced at
24h after administration of Ge-132 but was not detected in the sera at 12, 36, or 48 h after administration.
The antiviral activity of sera from Ge-132-treated mice was inactivated by treatments with trypsin, low pH,
and anti-IFNy antiserum. The inactivated preparations of serum IFN induced by Ge-132 did not exhibit
antitumour activity when administered to tumour-bearing mice. These results suggest that antitumour activity
in the sera of Ge-132-treated mice may be expressed through activities of Ge-132-induced lymphokine(s), such
as IFNy.
Certain immunopotentiators, derived from a variety
of sources, have not only an antitumour effect
(Mastrangelo et al., 1981), but also induce inter-
feron (IFN) production in vivo (Matsubara et al.,
1980). Some immunopotentiators, as well as IFN,
have been reported to augment natural killer (NK)
cell activity, stimulate macrophages (MO) to become
tumouricidal, generate cytotoxic T lymphocytes
(CTL), and enhance various nonspecific immune
responses both in vivo and in vitro (Mastrangelo
et al., 1981; Vilcek et al., 1980). Carboxyethyl-
germanium sesquioxide [03(GeCH2CH2COOH)2],
an organogermanium compound originally
synthesized at Asai Germanium Research Institute,
Tokyo, Japan (Tsutsui et al., 1976), is an immuno-
potentiating agent (Arimori et al., 1981b;
Mizushima et al., 1980; Suzuki et al., 1984) with
IFN-inducing (Aso et al., 1985; Miyao et al., 1980)
and antitumour activities (Kumano et al., 1980;
Arimori et al., 1981a; Satoh & Iwaguchi, 1979).
Acute and chronic toxicities of the compound were
determined in Wistar rats (acute and chronic) or
beagle dogs (chronic) by i.v. (125-500mgkg-1) or
oral (30-3,000mgkg-1) administration. At all doses
examined, no significant toxicity was detected
(Miyao et al., 1980; Nagata et al., 1978). The
physiocochemical characteristics and pharmaco-
kinetics of the compound have been described
previously (Miyao et al., 1980; Tomisawa et al.,
1978). As an immunotherapeutic agent for cancer,
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this compound has undergone some clinical testing
in Japan.
The antitumour activity of Ge-132 in ascites
tumour-bearing mice was eliminated by the in vivo
administration of monoclonal anti-Thy 1.2
antibody (anti-Thyl.2 mAb), which has been
reported to cause a disappearance of Thy-1.2+ cells
from mice (Nakayama & Uenaka, 1985; Opitz et
al., 1982), or macrophage (MO) blockers, such as
trypan blue and carrageenan (Chaout & Howard,
1976; Hibbs, 1975). However, the antitumour effect
of Ge-132 was not blocked by in vivo treatment
with anti-asialo GM1 antiserum which has been
reported to eliminate NK cell activity (Habu et al.,
1981). This suggested that the protective effect
displayed by Ge-132 was expressed through the
function of T lymphocytes and/or MO (Suzuki,
1985a,b).
The elimination of T-cells by anti-Thy 1.2
antibody and complement has been shown to result
in the suppression of interleukin 2 (IL-2) (Muhlradt
& Opitz, 1982) and IFN gamma (IFNy) production
(Sonnenfeld et al., 1979), as well as the generation
of CTL (Wong et al., 1977). It has also been
reported that IL-2 production, CTL generation,
and the augmentation of NK cell activity may be
influenced by IFNy (Kasahara et al., 1983; Torres
et al., 1982; Weigent et al., 1983). The oral
administration of Ge-132 was reported to stimulate
the production of IFN y in the sera of mice (Aso et
al., 1985), and this type of IFN appears to be
produced by T lymphocytes (Chang et al., 1982;
Sonnenfeld et al., 1979). Therefore, in the present
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paper, we investigated the role of IFN y, one of the
lymphokines (Epstein, 1981) induced by Ge-132 in
the sera of mice, on the antitumour properties of
the compound.
Materials and methods
Mice and tumours
Eight-week-old male and female inbred BALB/c
and C57BI/6 mice were used (Suzuki, 1985a,b).
Ehrlich (allogeneic), and RL31 (syngeneic) ascites
tumours were serially passaged in BALB/c mice by
i.p. injection of 1 x 106 cells per mouse (Suzuki,
1985a,b).
IFN assay and IFN standard
Mouse IFN activity was assayed by a microplaque
reduction method (Suzuki & Pollard, 1982). The
reference standard of murine IFN (G-002-904-511)
was obtained from the Antiviral Substances
Program of the National Institute of Allergy and
Infectious Diseases, National Institute of Health,
Bethesda, MD, USA and used to standardize the
IFN titration.
Murine IFN y and anti-mouse IFN y antiserum
Murine IFN y (Osborne et al., 1979) was kindly
provided by Dr H.M. Johnson, University of Texas
Medical Branch, Galveston, TX. Anti-mouse IFN y
antiserum (anti-IFN y) was also supplied by Dr
H.M. Johnson. The anti-IFN y has been shown to
preferentially inactivate the antiviral activity of
IFN y in vitro while not reacting with IFN a or
IFN # (Osborne et al., 1980a,b).
Preparation ofsera
The C57B1/6 mice received a 100mgkg1 body wt
oral dose of Ge-132 or a 0.5ml per mouse oral dose
of saline as a control. Twelve to 48h later the mice
were sacrificed and blood samples were maintained
at 4°C overnight, centrifuged at 1,250g for 30min,
and the supernatants (serum specimens) were stored
at -70°C.
Inactivation ofIFN activity
Twenty ml of serum IFN (360Uml 1) obtained
from mice 24h after Ge-132 administration or
murine IFN y (400Uml-) were mixed with an
equal volume of anti-IFN y (400 IFN neutralizing
Uml-1) or normal rabbit serum (control) and kept
at room temperature for h (Osborne et al.,
1980a,b). Then, 0.5ml was injected i.p. to tumour-
bearing mice. The inactivation of the serum IFN
induced by Ge-132 and murine IFN y by trypsin or
acid pH treatment was performed as previously
described (Aso et al., 1985). Briefly, both IFN y
preparations were treated with 200 igml-l of
trypsin at 37°C for 2h or dialyzed against 0.1M
glycine-HCl buffer (pH2.0) at 4°C for 12h, and
then redialyzed against 0.1M PBS (pH7.0). After
inactivation, these preparations were stored at
-700C.
Antitumour assay ofserum specimens in vivo
One day before Ehrlich or RLd1 tumour cell
inoculation (1 x 105 cells per mouse, i.p.), BALB/c
mice received an i.p. injection of 0.5ml of either a
1:5 dilution of serum obtained from mice at various
intervals after oral Ge-132 (100mgkg-1 body wt)
administration, the same dilution of control serum
obtained from mice 24h after oral saline (0.5ml per
mouse) injection, a 5,000 Ukg-1 body wt i.p. dose
of murine IFNy, or a 100mgkg-1 body wt oral
dose of Ge-132. In some experiments, tumour-
bearing mice received an i.p. injection of serum IFN
inactivated by trypsin or acid pH treatments, or
with antiserum-inactivated IFN y. These treatments
of tumour-bearing mice were performed once every
other day for a total of 10 injections. Mice were
observed daily in order to determine the mean
survival days (MSD). Each experiment was
terminated 50 days after tumour inoculation, and
the percent survival was calculated from the
number of mice surviving more than 50 days. The
influence of these preparations on tumour growth
was evaluated by MSD and survival percent as
compared with controls (Suzuki, 1985a).
Statistical analysis
As described previously (Suzuki, 1985a,b),
statistical significance was determined by Student's
t-test or x2 analysis. The results were considered
significant if P<0.05.
Results
Antitumour activity ofsera
To determine the antitumour activity of sera
obtained 24h after Ge-132 administration,
20BALB/c mice bearing Ehrlich tumours were
treated i.p. with 0.5ml of a 1:5 dilution of the
serum from Ge-132-treated mice (Ge-mice) or
normal control mice. As a positive control, one
group of 30 mice was treated with a 100mgkg-I
body wt oral dose of Ge-132, and a group of 40
mice was injected orally with 0.5ml per mouse ofANTITUMOUR EFFECT OF SERA FROM GE-MICE 759
Table I Antitumour effect of sera from mice treated with or without Ge-132 on Ehrlich or RL&1 ascites tumours in mice
Mean
No. of survival days 50 day
Tumour-bearing mice treated with;a mice (Range) P survivors(%) P
A. Ehrlich carcinoma
Sera from mice treated with Ge-132 20 27.6(14->50) <0.001 8(40) <0.001
Sera from normal mice 20 19.5(15-23) NS 0
Ge-132 30 28.8(14->50) <0.001 11(37) <0.001
Saline (tumour control) 40 18.6(14-24) 0
B RLd'lJ leukaemia
Sera from mice treated with Ge-132 10 38.4(25-> 50) <0.001 4(40) 0.025
Sera from normal mice 10 24.6(23-34) NS 0
Ge-132 20 35.6(22->50) <0.001 9(45) <0.001
Saline (tumour control) 20 20.3(22-23) 0
aMice bearing 1 x 105 Ehrlich or RL31 tumour cells were treated with sera (0.1 ml per mouse, i.p.), Ge-132(l00mgkg-1
body wt, orally) or saline (0.5ml per mouse, orally) 24h before tumour inoculation and every other day thereafter for a
total of 10 treatments. Serum specimens were obtained from mice 24h after Ge-132 or saline injection.
saline as a tumour control. As shown in Table IA,
Ge-132 and serum from Ge-mice significantly
increased the MSD of tumour-bearing mice
compared to those of tumour controls conferring
37 and 40% survival, respectively. In order to
determine if sera from Ge-mice were also effective
against a syngeneic ascites tumour (RL&1) in vivo,
tumour-bearing mice were treated in the same
fashion as in the Ehrlich experiments. As shown
Table IB, sera from Ge-mice also inhibited the
growth of RLdl ascites tumours in BALB/c mice
(40% survival, P=0.025) as did Ge-132
administration (45% survival, P<0.001), while all
control mice treated with saline or normal mouse
serum died within 34 days after tumour inoculation.
Thus, sera from Ge-mice were as active in vivo
against Ehrlich and RLS1 ascites tumours as Ge-
132 administration.
Dose response effect ofsera
Various dilutions of sera obtained 24h after
administration of Ge-132 were injected into mice
bearing Ehrlich tumours. Eight groups of tumour-
bearing mice (20 mice each) received i.p. injections
of 0.5ml of a 1:1 (0.5ml), 1:4 (0.12ml), 1:16
(0.03ml), or 1:64 (0.007ml) dilution of serum
obtained from Ge-mice or normal mice. As
illustrated in Figure 1, significant antitumour
activity of sera from Ge-mice was noted at dosages
of 0.5ml per mouse (70% survival, P<0.001) and
0.12ml per mouse (40% survival, P=0.002), while
<0.03ml per mouse and all concentrations of
normal mouse serum had no effect. These results
indicate that the antitumour properties of sera from
Ge-mice was dose dependent.
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Figure 1. Dose response protective effect of sera from
mice treated with Ge-132 (Ge-mice) against Ehrlich
ascites tumours in vivo. Mice (20 mice each) bearing
1 x 105 Ehrlich ascites tumour cells were treated i.p.
with 0.5ml of various dilutions of sera obtained from
normal (0) or Ge-mice (0), one day before and one
day after tumour inoculation, and every 2 days
subsequently for a total of 10 treatments.
Correlation between antitumour activity of sera and
appearance ofIFN
To determine if there was a correlation between the
appearance of IFN and the antitumour activity
induced by Ge-132, sera were harvested after an
oral dose of Ge-132 (100mgkg-1 body wt) every
6h for 48h. As shown in Figure 2, IFN appeared
18h after Ge-132 administration with maximum
levels (360Uml-1) detected at 24h and gradually
decreased thereafter until 42h when no IFN was
observed. Sera obtained from mice 12, 24, 36 and
48h after Ge-132 administration, and labelled A, B,
C, and D, respectively, were tested for their
antitumour activity in Ehrlich-bearing mice. Five
groups (20 mice each) were treated i.p. with 0.5ml
of a 1:5 dilution of specimens A to D or 0.5 ml per
mouse of saline, and observed for survival. As
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Figure 2. Antitumour activity of sera obtained from mice various times after Ge-132 administration.
Tumour-bearing mice received i.p. injections of sera (every other day, 10 total treatments, beginning one day
before tumour inoculation, 0.1 ml per mouse) obtained from mice 12h (A,,-), 24h (B, 0), 36h (C, A) or
48h (D, Cl) after oral Ge-132 (100mgkg- body wt) or saline (0.5ml, 0) administration.
shown in Figure 2, specimens A, C, and D had no
antitumour activity, while samples B and C
produced 40% (P<0.001) and 10% survival,
respectively. Therefore, the maximum antitumour
activity correlated with the highest IFN titre which
was noted 24h after Ge-132 administration.
Inactivation ofIFN activity
To determine if the serum IFN induced by Ge-132
was responsible for the observed antitumour effect,
IFN activity was inactivated by treatment with
trypsin, acid pH or anti-IFN y. The IFN activity
was completely inactivated by dialyzing against
0- 8-
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acidic buffer and trypsin treatments. In addition,
the IFN activity was neutralized by treatment with
anti-IFN y, as well as the murine IFN y. Since it
has been reported (Osborne et al., 1980a,b) that
this antiserum did not neutralize the antiviral
activity of IFN a or IFN f,, the IFN in sera from
Ge-mice was confirmed as an IFN y. The anti-
tumour activities of inactivated sera were next
evaluated in mice bearing Ehrlich tumours. Groups
of mice (10 mice each) were treated with inactivated
or uninactivated sera and a group of 30 mice
treated with saline was served as a tumour control.
As shown in Figure 3, while sera kept at 37°C for
2h (control for trypsin digestion) and 4°C for 12h
Time (d) after tumour inoculation
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Figure 3. Antitumour activity of inactivated sera from mice treated with Ge-132 (Ge-mice) against Ehrlich
ascites tumours in vivo. Tumour-bearing mice received i.p. injections of 0.5 ml saline per mouse (-), or sera
from Ge-mice which were subjected to pH 2.0 dialysis (4°C, 12h, A), pH 7.0 dialysis (4°C, 12h, A), trypsin
treatment (200pgm l-1, 37°C, 2h, *), or incubation without trypsin at 37°C (2h, EO), every 2 days for a total
of 10 treatments.
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Figure 4. Failure of protection of tumour-bearing mice by two IFN preparations treated with anti-IFN y
antiserum. 20ml of serum IFN (360 Uml- of IFN activity) obtained from Ge-mice and murine IFN y
(400Uml-1 of IFN activity) were treated with the same amount of anti-mouse IFN y antiserum (400 IFN
neutralizing Uml-1), and 0.5ml of these preparations was injected to mice bearing 1 x IO' Ehrlich cells
(neutralized serum IFN, *; neutralized murine IFN y, *). As positive or negative controls, tumour-bearing
mice were given i.p. 0.5ml of serum IFN (4,500 IFN Ukg-I body wt, A), murine IFN y (5,000 IFN Ukg-
body wt, C]), and saline (0).
(control for dialysis) protected 50% (P<0.001) and
40% (P<0.001) of the mice, respectively, serum
exposed to pH 2.0 or trypsin treatment did not
influence survival. In addition, when IFN-
containing samples were treated with anti-IFN y,
no antitumour effect was noted in a group of 10
tumour-bearing mice (Figure 4). Increased survival
was observed in mice treated with murine IFN y
(5,000 Ukg- body wt, 20 mice, 40% survival,
P<0.001), or IFN-containing serum from Ge-mice
(4,500Ukg-' body wt, 40% survival, 20 mice,
P<0.001). The tumour controls (30 mice) died
within 23 days of inoculation.
Discussion
The antitumour activity of sera obtained from Ge-
mice against syngeneic (RL31) or allogeneic
(Ehrlich) ascites tumours in mice appeared similar
to that observed with the compound itself. In
addition, the serum-mediated antitumour effect
correlated with IFN levels present and this
association was confirmed by kinetic and
inactivation studies. The maximum antitumour
activity in the serum was observed at the time of
the highest serum IFN titer (24h after Ge-132
administration). The inactivation of the IFN
activity in sera from Ge-mice was accomplished by
treatments with acid pH, trypsin or anti-IFN y and
abolished antitumour activity. The serum IFN
induced by Ge-132 in mice was identified as IFN y
since its activity was eliminated by treatment with
low pH and anti-IFN y. These results indicate that
the antitumour activity of the compound in mice
bearing experimental ascites tumours is
reconstituted by administration of the IFN y
containing sera from Ge-mice.
As compared to IFN a and I, IFN y has been
demonstrated to be a more potent mediator of
antitumour activities (Crane et al., 1978). Therefore,
repeated administration of mouse IFN y
preparations resulted in the marked inhibition of
the growth of transplantable murine tumours and
increased the survival of tumour-inoculated mice
(Crane et al., 1978; Salvin et al., 1975; Gresser,
1983). On the other hand, the antitumour activity
of Ge-132 appears to involve MO, since the
administration of MO blockers prevented the
expression of the antitumour activity of Ge-132
(Suzuki, 1985a), the passive transfer of MO from
Ge-mice conferred antitumour resistance to
untreated tumour-bearing mice (Suzuki, 1985b),
and MO from Ge-Mice also had cytotoxic
properties in vitro against certain tumours which
were sensitive to the antitumour activity of Ge-132
in vivo (Suzuki, 1985b). Some reports (Kleinschmidt
& Schultz, 1982; Robert & Vasil, 1982) suggest that
the induction of tumouricidal MO from a resting
state requires IFN y which induced the priming step
(Pace et al., 1982) in MO activation, or acts as a
cofactor associated with M4-activating factor
(Mannel & Falk, 1983). In addition, it was also
demonstrated that the in vivo administration of
anti-Thyl.2 mAb, effectively prevented the
expression of antitumour activity of Ge-132
761762 F. SUZUKI et al.
(Suzuki, 1985a). As presented here, the antitumour
activity of Ge-132 appeared to be expressed
through the induction of lymphokine(s), such as
IFN y, and since lymphokines have been shown to
be produced by T lymphocytes (Epstein, 1981), it is
possible that the activity of Ge-132 against tumours
may be due to the following properties: (i) the
compound exhibits antitumour activity which can
be blocked by the exogenous administration of T-
cell or MO blockers, (ii) MO obtained from Ge-mice
display antitumour activity in vivo and in vitro, (iii)
sera from Ge-mice contain IFN y, one of the
lymphokines which is produced by T-cells, (iv)
lymphokine(s), or IFN y, can activate MO to
become tumouricidal. This suggests that
lymphokine(s) such as IFN y induced by the
compound, may activate MO to become
tumouricidal and mediate the antitumour activity
observed in mice treated with Ge-132.
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